Literature DB >> 12039895

Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones.

Ralf René Reinert1, Adnan Al-Lahham, Rudolf Lütticken, Mechthild Boos, Franz-Josef Schmitz.   

Abstract

Fourteen pneumococcal strains isolated in three nationwide studies were characterized for amino acid changes in the enzymes GyrA, GyrB, ParC and ParE, and for the in vitro activity of eight fluoroquinolones and the new non-fluorinated quinolone BMS 284756. Gemifloxacin and BMS 284756 exhibited the best in vitro activity against all 14 isolates tested. In nine of the 14 isolates mainly classical alterations in ParC (D83N/Y, S79Y/F), as well as rarer alterations such as S80P and D78N, contributed to the decreased susceptibility to fluoroquinolones. In two of the 14 isolates the classical alteration in GyrA (S81F) was found. In only one isolate did alterations in ParC and GyrA exist in parallel.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12039895     DOI： 10.1093/jac/dkf036

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  5 in total

1.  Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.

Authors:  E Azoulay-Dupuis; J P Bédos; J Mohler; P Moine; C Cherbuliez; G Peytavin; B Fantin; T Köhler
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Characterization of levofloxacin non-susceptible clinical Streptococcus pyogenes isolated in the central part of Italy.

Authors:  D Petrelli; M C Di Luca; M Prenna; P Bernaschi; A Repetto; L A Vitali
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-05       Impact factor: 3.267

3.  Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.

Authors:  Ralf René Reinert; Susanne Reinert; Mark van der Linden; Murat Y Cil; Adnan Al-Lahham; Peter Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.

Authors:  E Azoulay-Dupuis; J P Bédos; J Mohler; G Peytavin; R Isturiz; P Moine; V Rieux; C Cherbuliez; J C Péchère; B Fantin; T Köhler
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

5.  Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.

Authors:  Samir N Patel; Roberto Melano; Allison McGeer; Karen Green; Donald E Low
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-01-18       Impact factor: 3.944
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.